Study associates long-term smoking cessation with reduction in epigenetic age acceleration
LONGEFI Signal
How this development was scored.
How authoritative and verifiable the underlying source is.
How prominent or noteworthy the development is based on its editorial classification.
How close this type of development sits to meaningful human clinical impact.
How strongly the development connects to companies and commercial or strategic context.
Measures significance, not direction or investment attractiveness.Methodology
A high LONGEFI Signal means the development is significant — not that it is positive news, a good investment, or expected to increase a company's share price.
Significance only. Direction-neutral: negative developments can score just as high. Not an investment rating, not a forecast, not a recommendation.
Event tier C · Tier ceiling 74 · LONGIFI_SIGNAL_V1
Quick take
A retrospective study in Geroscience reports that smoking cessation is associated with a dose-response reduction in biological age acceleration, with former smokers of over 20 years approaching the epigenetic profiles of never-smokers.
What happened
Researchers analyzed data from 1,911 adults aged 50-84 years from the National Health and Nutrition Examination Survey (NHANES) 1999-2002 to investigate biological aging reversibility.
Epigenetic age acceleration (EAA) was evaluated across six DNA methylation clocks: HorvathAge, HannumAge, SkinBloodAge, PhenoAge, GrimAge2, and DunedinPoAm.
Current smokers exhibited the highest EAA across all measured clocks, whereas former smokers demonstrated a dose-response reduction in EAA linked to longer cessation durations.
Former smokers with 20 or more years of cessation showed a reduction in GrimAge2 acceleration (beta = -12.66 years; 95% CI: -14.56, -10.75), which approached the levels of never-smokers (beta = -13.88 years; 95% CI: -15.70, -12.05).
Restricted cubic spline analysis indicated rapid biological aging declines during the first decade post-cessation, with continued declines persisting beyond 20 years for GrimAge2 and DunedinPoAm.
Why it matters
The findings provide clinical cohort evidence of the potential reversibility of environmental and behavioral epigenetic damage.
The study highlights the high sensitivity of second-generation (GrimAge2) and third-generation (DunedinPoAm) methylation clocks to behavioral changes, suggesting their suitability for monitoring long-term health span interventions.
Market impact
The demonstrated utility of GrimAge2 and DunedinPoAm in capturing long-term physiological changes supports the commercial development of advanced epigenetic tests as reliable diagnostic tools.
The multi-decade timeline required to naturally approach never-smoker biological baseline levels highlights a major market opportunity for therapeutic interventions designed to accelerate epigenetic repair and cellular rejuvenation.
What comes next
Further research validating whether targeted longevity interventions can accelerate the rate of epigenetic age reduction faster than natural cessation timelines.
Sources
- NCBIPUBMED:LONGEVITY_RESEARCH